| Naslov: | Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients |
|---|
| Avtorji: | ID Kopač, Maruša, Klinika Golnik (Avtor)
ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Avtor)
ID Korošec, Peter, Klinika Golnik, Fakulteta za farmacijo (Avtor)
ID Bidovec, Urška, Klinika Golnik (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Vantur, Romana, Klinika Golnik (Avtor)
ID Škrgat, Sabina, Klinika Golnik, Medicinska fakulteta UL, Univerzitetni klinični center Ljubljana (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (805,99 KB)
MD5: 2D1E19734BDB21EEC30F6F74C9643323
 URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-4426/12/1/70
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction. |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Švica |
|---|
| Založnik: | MDPI |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 1-12 |
|---|
| Številčenje: | Vol. 12, iss. 1 |
|---|
| PID: | 20.500.12556/DiRROS-14720  |
|---|
| UDK: | 616.2 |
|---|
| ISSN pri članku: | 2075-4426 |
|---|
| DOI: | 10.3390/jpm12010070 |
|---|
| COBISS.SI-ID: | 92821507 |
|---|
| Avtorske pravice: | © 2022 by the authors |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Maruša Kopač Šokić in Matija Rijavec sta enakovredna prva avtorja;
Opis z dne 11. 1. 2022;
Članek št. 70;
|
|---|
| Datum objave v DiRROS: | 13.01.2022 |
|---|
| Število ogledov: | 950 |
|---|
| Število prenosov: | 549 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
